A 58-Year-Old Man With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease

Pashna Munshi, MD, comments on available treatments for steroid-refractory chronic graft-versus-host disease (cGVHD), including ruxolitinib, and discusses challenges to diagnosis and management of the disease.